Table 1.

Demographic and clinical characteristics of the TRS Group and Non-TRS Group

Variables	TRS Group n = 79	Non-TRS Group n = 182	Statistic Values
General information
Age (years)	41.8 [11.1]	43.9 [11.5]	t = 1.375, P = 0.170
Sex: Male/Female (n)	47/32	98/84	Chi = 0.712, P = 0.400
Follow-up duration (days)	6139.7 [3692.6]	4477.8 [2269.7]	t = −3.708, P < 0.001
Duration before meeting TRS (days)	3195.2 [3148.8]	–
Clinical index prior to treatment introduction
Age at onset (years)	24.0 [8.30]	29.4 [9.63]	t = 4.306, P < 0.001
Premorbid social adjustment	4.71 [3.15]	3.61 [2.88]	t = −2.723, P = 0.007
DUP (months)	9.61 [16.5]	21.9 [47.8]	t = 1.976,
DUP median	3.00	3.75	P = 0.049
Mode of onset: Acute/Insidious (n)	38/41	74/108	Chi = 1.245, P = 0.264
Clinical index related to FEP
Duration of initial hospital admission (days)	87.9 [205.6]	53.3 [49.4]	t = −1.476, P = 0.144
GAF after FEP	50.1 [16.6]	61.0 [13.0]	t = 5.176, P < 0.001
GAF > 70 (n)	11	52	Chi = 6.454, P = 0.011
CP-dose for FEP treatment (mg)	562.4 [410.5]	703.4 [437.6]	t = 2.405, P = 0.017

Abbreviations: CP chlorpromazine, DUP duration of untreated psychosis, FEP first-episode psychosis, TRS treatment-resistant schizophrenia